Diagnos (TSE:ADK) has released an update.
DIAGNOS Inc. has renewed its distribution agreement with Labtician, celebrating the integration of its AI-based image analysis for diabetic retinopathy into Labtician’s offerings in Ontario. This collaboration aims to enhance eye care for diabetics by improving access to screenings through Ontario’s health system, thus addressing patient compliance and reducing vision loss risks. The partnership reaffirms both companies’ commitment to advancing healthcare solutions and expanding DIAGNOS’ presence in the Canadian market.
For further insights into TSE:ADK stock, check out TipRanks’ Stock Analysis page.
